Project Description

Pete Ratcliffe


Pete has 20 years’ commercial, operations management & advisory experience in global strategic consultancy roles across Europe, the US, Asia & Australia.

He is the founder, Chairman and CEO of Agincourt Advisory, a private market advisory firm specializing in diversified alternative assets & pursing opportunistic interests in Private Debt, Real Estate, Private Equity & Venture asset classes, focusing on a broad range of industries & sectors including Healthcare, Technology, Renewable Energy, Clean / Green Tech, Financial Services & Fintech, Agriculture & Ag Tech, Commercial Realty, Education, Aged Care & Tourism.

Agincourt provides robust portfolio diversification strategies by identifying & responding to special opportunities across divergent asset classes & sectors with low correlation to the volatility of public markets.

Pete is also a director of Agincourt Bio Consulting pty ltd which he founded after working in the global Life Science strategic consultancy arenas in Europe, the US, Asia and Australia.

Agincourt Bio Consulting is a boutique advisory firm, specializing in providing uniquely tailored approaches to partner identification, commercialization strategies and targeted exposure to Investor networks for the Healthcare, Life Science and Medical Device industries.

Agincourt Bio Consulting works with biotech, tier 1 and 2 pharma, medical device and diagnostic clients supporting corporate strategic planning, licensing, strategic business development, alliance management, IP commercialization, capital raising, cross border engagement & joint venture’s taking advantage of the IP appetite from Asian markets.

Prior to founding Agincourt Pete headed up the Healthcare business within Datamonitor (part of the Informa group), a leading market analyst firm providing strategic research, bespoke high level, complex consultancy and commercial, strategic and business operations advisory services.

Pete joined Datamonitor in London supporting clients across Europe & the US. In 2007 returned to Australia to manage the Asia Pacific healthcare operation.

Past roles include Australian Sales Director for Truven Health Analytics, a US based healthcare big data and global health economics outcomes provider, acquired by IBM Watson health in 2016 for $2.6 billion USD.